Teva Discloses `Suspect Practices’ In Filing With U.S. Securities Regulators

Teva Pharmaceuticals has informed the U.S. Securities and Exchange Commission that a probe of its international operations disclosed business practices in Latin America, Russia and Eastern Europe that could violate U.S. anti-bribery laws.

“In the course of our investigation, which is continuing, we have identified issues in Russia, certain Eastern European countries, and certain Latin American countries that could potentially rise to the level of FCPA [Foreign Corrupt Practices Act] violations and/or violations of local law,” Teva wrote in its report to the SEC, dated Oct. 31.

“Teva has provided and will continue to provide documents and other information to ...